INTRODUCTION
This me dic a l p osit ion statement developed by the Romanian Association for Pancreatic Pathology (APPR) encompasses the main diseases ass o ci ate d w it h exo cr ine pancreatic insufficiency (EPI), defined as an inadequate pancreatic enzyme activity to digest food generally due to either insufficient enzyme production, insufficient enzyme activation, or to early enzyme degradation. Recognition of this condition helps avoiding malnutritionrelated morbidity and mortality, along with impaired quality of life (QoL) associated with low body mass index.
J Gastrointestin Liver Dis, March 2015 Vol. 24 No 1: 117-123 present EPI in 10 years after diagnosis and almost all after 20 years [2] . In autoimmune pancreatitis patients, EPI occurs in 80% of cases and improves under steroids [3] .
Recovery of the pancreatic function after acute pancreatitis varies between three months and four years [3] , but the severity of EPI is not directly related to the severity of the acute episode [4] . Pancreatic head tumors present with EPI at the diagnosis, and this aggravates in two months of evolution [5] .
Pancreatectomy performed for pancreatic tumors is associated with EPI in about 70% of the cases [6] , especially because duodenectomy diminishes the CCK release and induces an asynchronism between gastric emptying of the nutrients and the bilio-pancreatic secretion [7] . Stenosis of the pancreatic duct anastomosis aggravates pancreatic insufficiency [7, 8] . Distal pancreatectomy is transiently related to pancreatic insufficiency [8] .
Celiac disease is associated with EPI in one third of the patients because of the reduced pancreatic stimulation [9] .
Cystic fibrosis (CF) with duct obstruction is associated with EPI in 85% of the patients [10] .
Exocrine pancreatic insufficiency is found in 30% of the patients with inflammatory bowel disease [11] and in association with autoimmune pancreatitis. It is present particularly in patients with loose stools, many stools/day and those with previous surgery; however, it is reversible in most patients [12] .
Diabetes mellitus is associated with pancreatic atrophy due to the lack of the trophic insulin effects, and also due to diabetic enteropathy with the interruption of the enteroneuropathic reflexes or arteriopathy in type 2 diabetes. The prevalence of severe EPI was found to be 22% and it was higher in early onset of endocrine failure, long-lasting diabetes mellitus and low body mass index levels [13] . However, when alcohol intake was excluded, EPI occurred in only 5% of these patients [14] .
Exocrine pancreatic insufficiency secondary to gastrointestinal Billroth II anastomosis or antrectomy is caused by the dyssinergism between the pancreatic enzymes delivery and the food particles, the decrease of neuro-hormonal pancreatic stimulation, and the intestinal bacterial overgrowth [15] .
Diagnosis of EPI
The main clinical consequence of EPI is fat maldigestion and malabsorption resulting in steatorrhea. Patients have low circulating levels of micronutrients, fat soluble vitamins and lipoproteins. Various direct and indirect pancreatic function tests are available to diagnose EPI. Direct testing is the most sensitive one, but it is unpleasant for patients and is only used in specialized centers. Endoscopic function testing provides similar results to the standard secretin test, but takes about one hour to be performed and is rarely used [16] . Secretin-magnetic resonance pancreatography and secretin-endoscopic ultrasonography allow a quantitative assessment of pancreatic function, even in patients with a mild exocrine insufficiency, by assessing both duodenal filling and pancreatic ductal changes. These procedures are expensive, but they are considered as the most specific and sensitive tests for diagnosing EPI [17] [18] [19] . Indirect pancreatic function tests are non-invasive and assess the effects of pancreatic enzymes in the gastrointestinal tract such as undigested food or enzymes (e.g. stool human fecal elastase-1, FE-1).
Determination of FE-1 levels uses an enzyme-linked immunosorbent assay specific for this human protein.
The normal value is >200 mg/g, and the lower the value is, the higher the probability of EPI [20] . Although generally pancreatic function testing requires discontinuation of PERT, FE-1 levels are not affected by pancreatic enzyme replacement therapy (PERT) so there is no indication to stop therapy. FE-1 has a better sensitivity (72%) for severe EPI [21] than for mild to moderate forms (sensitivity of 54%); test specificity is 79% for diagnosing mild to moderate EPI [22] . Its specificity is lower in cases of diarrhea, due to dilution [20] , in diabetes [22] and isolated enzyme deficiencies [23] .
The 13 C-mixed triglyceride test ( 13 C-MTGT) is more extensively used for the diagnosis of EPI. The test sensitivity Table I . Level for EPI is 90% [24] . The duration of the test (4 to 6 hours) is the major drawback. The test results could also be unreliable in case of intestinal malabsorption, severe liver disease and/ or respiratory insufficiency.
Indication for PERT
To avoid malnutrition-related morbidity and mortality in patients with chronic pancreatitis (CP), it is essential to start PERT as soon as EPI is diagnosed [25] . PERT improved pain and quality of life (QoL) for patients with pancreatic cancer in a multicenter observational study (n= 294) [26] . Improvement in the coefficient of fat absorption (CFA) and the coefficient of nitrogen absorption (CNA), as well as the stool aspect were noted in randomized controlled trials (RCTs) [27, 28] .
Postoperative PERT has a positive impact on long-term patient survival after operative treatment for CP and should be the standard treatment at the time of hospital discharge, even when no clinical signs of EPI are present [29] . Cystic fibrosis is associated with a variable degree of pancreatic insufficiency in the first year following diagnosis, according to FE-1 [30] . PERT is associated with CFA and CNA improvement in RCTs of pediatric CF [31] and generally contributes to the increased survival in CF [32] .
Therapy
Therapeutic options include dietary measures, PERT, and treatment of the basic disease (pancreatic duct decompression). 
Efficacy outcome measures
The response to therapy is based on the coefficient of fat absorption, the results of the breath test and on the weight balance and the stool aspect.
The CFA is the current standard for evaluating PERT efficacy. Values < 93% in adults and < 85% in children aged <6 months are considered abnormal. The CNA test is a secondary outcome as a measure of protein digestion. Weight gain is a useful parameter to measure during long-term follow-up. Stool frequency and stool characteristics can be useful surrogates of the therapeutic outcome.
Dietary management for EPI
The aim is to maintain an adequate intake and to correct nutritional deficiencies.
The diet to be followed in EPI is not specific but it should be well-balanced, with 35 kcal/kg body weight/day, 1-1.5 g/kg body weight/day of protein and 30% fat, rich in carbohydrates, low in fiber, sufficient to maintain the nutritional status [33, 34] . In order to improve energy and protein intake, the diet should be tailored to individual needs and micronutrient intake should be adequate. Patients with EPI should be encouraged to consume small, frequent meals and to abstain from alcohol. Low-fat diets are inferior in terms of total energy, and intake of fat-soluble vitamins is not recommended [35] . A normal fat diet is recommended. In the case of CF, a high fat diet is acceptable for nutritional goals in conjunction with appropriate enzyme supplementation [36] . In case of severe steatorrhea, medium-chain triglycerides could be consumed in several (5-7) small meals, although this does not generally provide sufficient energy and it may also increase the risk of ketogenesis [37] . As the ingestion of fiber-rich foods including vegetables inhibits lipase activity by > 50%, a reduced fiber intake is considered beneficial in EPI [37] .
PERT Pancreatic enzyme replacement therapy is the mainstay of EPI treatment. The objective is to deliver sufficient enzymatic activity into the duodenal lumen simultaneously with the meal in order to optimize digestion and absorption of nutrients.
Several RCTs have demonstrated that PERT improves fecal fat excretion in patients with EPI [26] [27] [28] . A systematic review of 12 RCTs demonstrated that PERT leads to significant reduction of fecal fat excretion versus placebo, but does not completely normalize fecal fat excretion [38] . The QoL may also be improved [39] .
Key requirements for a pancreatic enzyme formula include high lipase activity, protection of the lipase from being destroyed by gastric acid, ease of mixing with the chyme (and exit from the stomach intact) and rapid release out of lipase from the protective enteric coating into the duodenum. Since the lipase of porcine pancreatin is destroyed by proteases and acids, protection from gastric acidity is essential. The best particle size for rapid release from the stomach through the pylorus is < 2mm in diameter, as these particles can exit the stomach with solid food. Current preparations contain porcine pancreatic extract encapsulated in micro-tablets or mini-microspheres with pH-sensitive enteric coating, as recommended by all major current European national consensus guidelines [18, 35, 40] . As exogenous enzymes should exert their action on the ingested meal and as gastric emptying of the enzymes should occur in parallel with nutrients in order to optimize digestion and absorption, PERT preparations should be given at every instance during a meal or snack, or at a short time after starting the meal/snack. This improves recovery rates as compared with preparations given before meals [41] .
Appropriate doses for therapy start are 40,000 IU lipase/ meal for CP or pancreatic surgery [35, 42] , adjusted according to EPI severity, fat diet content, degree of symptom control, and maintenance of good nutritional status. They can be doubled or tripled based on the clinical need [42] .
As a rule, lipase replacement is considered to be the most important component of PERT, and conversely, dosage of PERT is quantified as units of lipase as the most relevant measure of its clinical efficacy. This is due to the fact that even in case of complete absence of pancreatic exocrine secretion, > 80% digestion of starch and protein may be maintained by salivary, gastric and intestinal brush border enzymes, but failure of lipid digestion cannot be compensated [43] .
Side effects of PERT PERT is considered to have an acceptable safety and tolerability profile. A maximum dose of 10,000 IU lipase/kg body weight is recommended [44] . Doses of 72,000 USP lipase/meal were associated with complication rates of 7.8%-13%, including abdominal pain, abdominal distension, and diarrhea [27] , similar to placebo [28] .
Treatment failure When clinical steatorrhea or decreased nutritional status persist despite correct dosage, compliance and intestinal bacterial overgrowth should be checked [35] . Proton pump inhibitor (PPI) use is appropriate for non-enteric coated tablets. Recent guidelines still recommend PPI use in case of EPI resistant to treatment [35, 42] .
CONCLUSIONS
The recommendations formulated represent the consensus guiding the management of EPI and are based on clinical experience rather than clinical data. The suggested diagnostic tests are not compulsory when clinical suspicion exists and EPI is expected.
In assessing pancreatic exocrine function, its etiology should be considered. The EPI due to chronic pancreatitis, acute pancreatitis or upper gastrointestinal surgery increases the risk of poor nutrition, leading to complications and higher mortality. Weight loss negatively influences survival in patients with chronic pancreatitis and pancreatic cancer.
Diagnosis of EPI remains a challenge due to the lack of a reliable test available to identify mild-to-moderate forms of the condition. The FE-1 test, although well established, may not reliably measure mild-to-moderate EPI. The breath test is reliable for the diagnosis and for assessing treatment efficacy but it takes longer to perform. Pancreatic enzyme replacement treatment is the mainstay of EPI treatment.
Treatment with enteric-coated mini-microspheres is recommended at every meal, and progressively increasing doses may be given based on an individual's weight and clinical symptoms.
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